Drugs /

telaglenastat

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable inhibitor of glutaminase, with potential antineoplastic activity. Upon oral administration, CB-839 selectively and irreversibly inhibits glutaminase, a mitochondrial enzyme that is essential for the conversion of the amino acid glutamine into glutamate. By blocking glutamine utilization, proliferation in rapidly growing cells is impaired. Glutamine-dependent tumors rely on the conversion of exogenous glutamine into glutamate and glutamate metabolites to both provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival.

Clinical Trials

View Clinical Trials for telaglenastat

Telaglenastat has been investigated in 17 clinical trials, of which 11 are open and 6 are closed. Of the trials investigating telaglenastat, 6 are phase 1 (5 open), 6 are phase 1/phase 2 (3 open), and 5 are phase 2 (3 open).

EGFR Exon 19 Deletion, EGFR L858R, and ER Negative are the most frequent biomarker inclusion criteria for telaglenastat clinical trials.

Malignant solid tumor, non-small cell lung carcinoma, and breast carcinoma are the most common diseases being investigated in telaglenastat clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Telaglenastat
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Telaglenastat
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating telaglenastat and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cb-839, glutaminase inhibitor cb-839, telaglenastat
Drug Target(s) [2]:
GLS
NCIT ID [1]:
C114381

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.